Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 5/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 11/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL8589228 | 0.83 | BHMT (0.47) | BHMTRNPEPBHMT2 | |
| Methionine SCHEMBL8763034 | 0.83 | BHMT (0.47) | BHMTRNPEPBHMT2 | |
| Methionine SCHEMBL8589231 | 0.83 | BHMT (0.47) | BHMTRNPEPBHMT2 | |
| Trifluoroacetic Acid SCHEMBL6557113 | 0.81 | RNPEP (0.40) | BHMTRNPEPDPP4DPP7BHMT2 | |
| Trifluoroacetic Acid SCHEMBL6557109 | 0.81 | RNPEP (0.40) | BHMTRNPEPDPP4DPP7BHMT2 | |
| Trifluoroacetic Acid SCHEMBL2493278 | 0.79 | ALOX15 (0.48) | DPP4DPP7DPP9DPP8KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2496044 | 0.79 | DPP4 (0.41) | DPP4DPP7DPP9DPP8KCNH2 | |
| Trifluoroacetic Acid SCHEMBL9439513 | 0.79 | S1PR1 (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL2500137 | 0.78 | DPP4 (0.35) | DPP4DPP7DPP9DPP8KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2496872 | 0.78 | DPP8 (0.38) | DPP4DPP7DPP9DPP8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | BHMT 1759/4885RNPEP 1225/4885DPP4 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.